Australia's most trusted
source of pharma news
Sunday, 23 February 2025
Posted 21 February 2025 AM
A first-in-class orphan drug has been approved by the Therapeutic Goods Administration, a month before it hits the desk of the Pharmaceutical Benefits Advisory Committee.
Specialised Therapeutics' Yorvipath is a daily subcutaneous injection indicated for the treatment of chronic hypoparathyroidism in adults. It's a prodrug of parathyroid hormone (PTH), which is produced at insufficient levels in people with hypoparathyroidism.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.